<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366960</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001708-41</org_study_id>
    <nct_id>NCT04366960</nct_id>
  </id_info>
  <brief_title>Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients</brief_title>
  <acronym>X-Covid 19</acronym>
  <official_title>Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a higher dose of low molecular weight&#xD;
      heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin&#xD;
      40 mg o.d.) in reducing thromboembolic events in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease-19 (COVID-19 ), which is caused by SARS-CoV-2 infection, are apparently&#xD;
      at high risk of venous thromboembolism (VTE), as a consequence of activation of the&#xD;
      hemostatic system which, in the most severe cases, can also be associated with the formation&#xD;
      of microthrombi and clinically relevant disseminated intravascular coagulation. Concerns&#xD;
      about the efficacy of thromboprophylaxis with standard doses of low-molecular-weight heparin&#xD;
      (LMWH) has been raised. Therefore, LMWH at higher doses than those recommended for&#xD;
      thromboprophylaxis is used in some hospitals, although no evidence exists yet of higher&#xD;
      efficacy of high doses compared to standard prophylactic doses. This practice might as well&#xD;
      increase the risk of major bleeding. The investigators designed a randomized trial comparing&#xD;
      standard prophylactic dose of subcutaneous enoxaparin (40 mg o.d.) with higher dose (40 mg&#xD;
      b.i.d) with the aim of testing whether high-dose thromboprophylaxis is more effective than&#xD;
      standard dose in preventing VTE in COVID-19 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label Multicentre Prospective Controlled Randomized Trial in patients with SARS-CoV-2 infection. Patients will be randomized 1:1 to 40 mg subcutaneous enoxaparin o.d. versus 40 mg enoxaparin b.i.d within 12 hours after hospitalization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of venous thromboembolism detected by imaging</measure>
    <time_frame>30 days</time_frame>
    <description>Deep vein thrombosis events diagnosed by serial compression ultrasonography and pulmonary embolism events diagnosed by computed tomography scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In hospital major complications</measure>
    <time_frame>30 days</time_frame>
    <description>death, venous thromboembolism, use of mechanical ventilation, stroke, acute myocardial infarction and admission to an intensive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deep venous thrombosis events</measure>
    <time_frame>30 days</time_frame>
    <description>Deep venous thrombosis events diagnosed by serial compression ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment</measure>
    <time_frame>30 days</time_frame>
    <description>Maximum sequential organ failure assessment (SOFA) score comparison between the two groups.&#xD;
The SOFA score ranges from 0 to 24. Higher SOFA score is associated with a greater risk of death or prolonged intensive care unit stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>30 days</time_frame>
    <description>To compare C-reactive protein levels as % above the upper reference limit [URL]) among the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>30 days</time_frame>
    <description>To compare Interleukin-6 levels as % above the upper reference limit [URL]) among the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>30 days</time_frame>
    <description>To D-dimer compare levels as % above the upper reference limit [URL]) among the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-troponin levels</measure>
    <time_frame>30 days</time_frame>
    <description>To compare hs-troponin levels as % above the upper reference limit [URL]) among the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Respiratory Distress Syndrome</measure>
    <time_frame>30 days</time_frame>
    <description>To compare the incidence of SARS-CoV-2-related Acute Respiratory Distress Syndrome (ARDS) between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>To compare length of hospital stay between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function</measure>
    <time_frame>30 days</time_frame>
    <description>To compare measures of right ventricular function at trans-thoracic echocardiography or CT between admission and follow-up, whenever available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary embolism events</measure>
    <time_frame>30 days</time_frame>
    <description>Pulmonary embolism events diagnosed by computed tomography scan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2712</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>40 mg subcutaneous enoxaparin o.d.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effects of 40 mg subcutaneous enoxaparin o.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg subcutaneous enoxaparin b.i.d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Effects of 40 mg subcutaneous enoxaparin b.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Subcutaneous enoxaparin</description>
    <arm_group_label>40 mg subcutaneous enoxaparin b.i.d</arm_group_label>
    <arm_group_label>40 mg subcutaneous enoxaparin o.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All-comers patients aged &gt;=18 years and admitted to hospital with laboratory-confirmed&#xD;
             SARS-CoV-2 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients admitted directly to an intensive care unit;&#xD;
&#xD;
          -  Estimated creatinine clearance &lt;15 ml/min/1.73m2;&#xD;
&#xD;
          -  Patients needing anticoagulant for prior indication;&#xD;
&#xD;
          -  Participants involved in other clinical trials;&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the investigator,&#xD;
             may either put the participants at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nuccia Morici, MD</last_name>
    <phone>+396444</phone>
    <phone_ext>2565</phone_ext>
    <email>nuccia.morici@ospedaleniguarda.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuccia Morici, MD</last_name>
      <phone>+026444</phone>
      <phone_ext>2565</phone_ext>
      <email>nuccia.morici@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

